Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

gideonblumenthal

Add ILCN as a preferred source
  • FDA Corner – Interview with Gideon Blumenthal, MD

    FDA Corner – Interview with Gideon Blumenthal, MD

    By

    Regulatory Agency Perspective

    By Erik J. Mac Laren, PhD In 2015, the US Food and Drug Administration (FDA) approved an unprecedented 7 new drugs or new uses for drugs for patients with lung cancer, an increase driven by the proliferation of targeted therapies in the area of thoracic oncology. The advent of precision medicine in oncology has raised…

View ILCN Archives

Provider Resources

Popular Articles

  • Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection

  • Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy

  • Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC

  • No “Known” Risk Factors: The Health Consequences of Radiation Therapy

  • Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging

  • No PFS, OS Benefit Seen in Final Results from PACIFIC-2

  • WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers

  • Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

  • A Holistic Approach to Patient Care